COMP <GO>
VRTX vs PFE // NET PROFIT MARGIN
Vertex Pharmaceuticals Incorporated (NASDAQ) VS. Pfizer Inc. (NYSE) • 15-METRIC TALLY: VRTX 8
— PFE 5
▲ NET PROFIT MARGIN LEADER: VRTX
LAST: $553.15 (-1.02%) • MKT CAP: $141.65B
net-margins
32.90%
LAST: $30.67 (+0.49%) • MKT CAP: $173.95B
net-margins
12.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRTX VS. PFE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRTX | PFE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.20% | 74.30% | +11.90 | VRTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.00% | 5.10% | +14.90 | VRTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 29.6x | 19.7x | +9.90 | PFE | /valuation <GO> |
| Free Cash Flow Yield | 2.33% | 5.32% | -2.99 | PFE | /fcf-yield <GO> |
| Operating Margin | 34.80% | 15.10% | +19.70 | VRTX | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 32.90% | 12.40% | +20.50 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.90% | -1.60% | +10.50 | VRTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.86 | 2.10 | +11.76 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | VRTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.9 | 63.6 | +0.30 | VRTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 1.05 | -0.03 | PFE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.2x | 20.5x | +11.70 | PFE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $141.65B | $173.95B | -$32.30B | PFE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRTX REV | PFE REV | VRTX GROSS % | PFE GROSS % | VRTX FCF | PFE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.00B | $62.58B | 86.2% | 74.3% | $3.19B | $9.07B |
| FY 2024 | $11.02B | $63.63B | 86.1% | 71.9% | -$790.3M | $9.84B |
| FY 2023 | $9.87B | $50.91B | — | — | $3.09B | $6.41B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRTX // BETA 1.02
PFE // BETA 1.05